ReviewExperimental and therapeutic medicine2023
Drug‑resistant
Review in Experimental and therapeutic medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Prevalence and associations of antibiotic resistance and biofilm formation with molecular determinants in clinical Acinetobacter baumannii isolates.Scientific reports · 2026Article
- Virulence and Resistance Mechanisms in Multidrug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Article
- Review
- Fatty acids from Hermetia illucens larvae disrupt membrane integrity in colistin-resistant Acinetobacter baumannii.BMC microbiology · 2026Article
- Article
- Analysis of Clinical Gram-Negative Carbapenem Resistant Acinetobacter baumannii and Klebsiella pneumoniae Isolates from Wounds of Patients at a Hospital Reveals Complex Resistome and the First Report of blaCurrent microbiology · 2025Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- Review
- Isolation and characterization of phages ΦZC2 and ΦZC3 against carbapenem-resistant Acinetobacter baumannii, and efficacy of ΦZC3 on A549 cells.Virology journal · 2025Article
- Exploration of Phosphoproteins inPathogens (Basel, Switzerland) · 2025Article
- High Prevalence of Virulence andPathogens (Basel, Switzerland) · 2025Article
- Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in hospitalized adult patients in the USA between 2018 and 2022.BMC infectious diseases · 2025Article
- Article
- Phenotypical and Molecular Characterization ofLife (Basel, Switzerland) · 2025Article
- Comprehensive molecular epidemiology of Acinetobacter baumannii from diverse sources in Nigeria.BMC microbiology · 2025Article
- The Evolution of Antimicrobial Resistance inAntibiotics (Basel, Switzerland) · 2025Review
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Exploring drug resistance genes inFrontiers in microbiology · 2025Article
- New Agents Are Coming, and So Is the Resistance.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial drug resistance is increasingly becoming an important problem that needs to be solved urgently in modern clinical practices. Infection caused by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.